Evidence map›Paper›PMID 28182657›Full record

ArticlePLoS neglected tropical diseases2017

Modeling the Potential for Vaccination to Diminish the Burden of Invasive Non-typhoidal Salmonella Disease in Young Children in Mali, West Africa.

Kristin Bornstein, Laura Hungerford, David Hartley, John D Sorkin, Milagritos D Tapia, Samba O Sow, Uma Onwuchekwa, Raphael Simon, Sharon M Tennant, Myron M Levine

Registry-linked trialAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07416461 (Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-Typhoidal Salmonella Disease), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07416461 recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-Typhoidal Salmonella Disease (VINS)

TypeobservationalSponsorInternational Vaccine InstituteRan2025 to 2027Enrolled10,000ConditionsInvasive Non-Typhoidal Salmonella Disease, Malaria, Malaria VaccineArmsR21/Matrix-M malaria vaccine
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Article
  3. Foodborne Infections andVaccines · 2024
    Review
  4. Article
  5. Surveillance for Invasive Salmonella Disease in Bamako, Mali, From 2002 to 2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  6. The American journal of tropical medicine and hygiene · 2018
    Article
  7. Article
  8. NontypicalProceedings (Baylor University. Medical Center) · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kristin BornsteinCenter for Vaccine Development and Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Laura HungerfordDepartment of Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.
David HartleyJames M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States of America.
John D SorkinDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Milagritos D TapiaCenter for Vaccine Development and Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Samba O SowCentre pour le Développement des Vaccins, Mali (CVD-Mali), Bamako, Mali, Africa.
Uma OnwuchekwaCentre pour le Développement des Vaccins, Mali (CVD-Mali), Bamako, Mali, Africa.
Raphael SimonCenter for Vaccine Development and Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Sharon M TennantCenter for Vaccine Development and Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.
Myron M LevineCenter for Vaccine Development and Institute for Global Health, University of Maryland School of Medicine, Baltimore, MD, United States of America.ORCID 0000-0002-5721-5040

Funding

University of Maryland Claude D. Pepper Older Americans Independence Center (UM-OAIC)P30AG028747 · NIA · UNIVERSITY OF MARYLAND BALTIMORE · PI Stephen L. Seliger · 2006 to 2026
$28.9M
Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2014 to 2018
$25.4M
NIAID NIH HHS U19 AI109776NIA NIH HHS P30 AG028747Wellcome Trust WT095967
6 · The paper itself

Abstract

backgroundIn sub-Saharan Africa, systematic surveillance of young children with suspected invasive bacterial disease (e.g., septicemia, meningitis) has revealed non-typhoidal Salmonella (NTS) to be a major pathogen exhibiting high case fatality (~20%). Where infant vaccination against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae has been introduced to prevent invasive disease caused by these pathogens, as in Bamako, Mali, their burden has decreased markedly. In parallel, NTS has become the predominant invasive bacterial pathogen in children aged <5 years. While NTS is believed to be acquired orally via contaminated food/water, epidemiologic studies have failed to identify the reservoir of infection or vehicles of transmission. This has precluded targeting food chain interventions to diminish disease transmission but conversely has fostered the development of vaccines to prevent invasive NTS (iNTS) disease. We developed a mathematical model to estimate the potential impact of NTS vaccination programs in Bamako. METHODOLOGY/PRINCIPAL

findingsA Markov chain transmission model was developed utilizing age-specific Bamako demographic data and hospital surveillance data for iNTS disease in children aged <5 years and assuming vaccine coverage and efficacy similar to the existing, successfully implemented, Hib vaccine. Annual iNTS hospitalizations and deaths in children <5 years, with and without a Salmonella Enteritidis/Salmonella Typhimurium vaccine, were the model's outcomes of interest. Per the model, high coverage/high efficacy iNTS vaccination programs would drastically diminish iNTS disease except among infants age <8 weeks. CONCLUSIONS/SIGNIFICANCE: The public health impact of NTS vaccination shifts as disease burden, vaccine coverage, and serovar distribution vary. Our model shows that implementing an iNTS vaccine through an analogous strategy to the Hib vaccination program in Bamako would markedly reduce cases and deaths due to iNTS among the pediatric population. The model can be adjusted for use elsewhere in Africa where NTS epidemiologic patterns, serovar prevalence, and immunization schedules differ from Bamako.

Indexed as

Immunization ProgramsChildChild, PreschoolDisease Transmission, InfectiousHospitalizationHumansInfantInfant, NewbornMaliModels, TheoreticalSalmonella InfectionsSalmonella VaccinesSurvival AnalysisVaccinationSalmonella Vaccines

Identifiers

PMID28182657
PMCPMC5300129

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.